Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

 Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

Shots:
  • Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer)
  •  Marketed as 150mg and 440mg multiple dose vials
  •  As per Dr. Reddy, it has four biosimilars commercialized in India
Click here to read full press release/ article Ref: Dr. Reddy Laboratories | Image: Dr Reddy’s

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post